Find Reports

Select Report Type

Learn More about Reports

Reimbursement Review

Displaying 1251 - 1258 of 1258

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 589 of 589

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 111 of 111

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 40 of 40

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1351 - 1375 of 2093

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Collaboration in Health Technology Assessment in Canada		Sep 6, 2019	Health Technology Review	Environmental Scan	Completed	ES0329-000
CADTH Pharmaceutical Reviews Update — Issue 10		Aug 22, 2019	Reimbursement Review	Pharmaceutical Review Update
Lutathera for Gastroenteropancreatic neuroendocrine tumors – Details	pcodr-provfund-10142-LutetiumLutathera_GEP_NETs.pdf 10142LutetiumLu177dotatateGEP-NET_fnRec_Post_01Aug2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_fnEGR_NOREDACT-ABBREV_Post_01Aug2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_fnCGR_NOREDACT_Post_01Aug2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_inRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_PAGFeedbackSummary_FINAL_Post_01Aug2019_draft.pdf 10142LutetiumLu177dotatateGEP-NET_SubmitterFeedback_2019-06-14_Post_01Aug2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_PatientFeedback_CNETS_2019-06-28_Post_01Aug2019_final.pdf 10142LutetiumLu177dotatateGEP-NET_COI_Post_01Aug2019_final.pdf	Aug 19, 2019	Reimbursement Review		Complete	PC0142-000
Brigatinib (Alunbrig) for Non-Small Cell Lung Cancer (NSCLC) – Details	pcodr_provfund-10167-BrigatinibAlunbrig_NSCLC.pdf 10167BrigatinibNSCLC_FnRec_approvedbyChair_NOREDACT_Post_01AUG2019_final.pdf 10167BrigatinibNSCLC_fnEGR_NOREDACT-ABBREV_01AUG2019_final.pdf 10167BrigatinibNSCLC_fnCGR_NOREDACT_POST01AUG2019_final.pdf 10167BrigatinibNSCLC_inRec_approvedbyChair_NOREDACT_Post_31May2019_final.pdf 10167BrigatinibNSCLC_PAGFeedbackSummary_FINAL_Post_01Aug2019_final.pdf 10167BrigatinibNSCLC_SubmitterFeedback_2019-06-14_Post_01Aug2019_final.pdf 10167BrigatinibNSCLC_PatientFeedback_LCC_2019-06-14_Post_01Aug2019_final.pdf 10167BrigatinibNSCLC_Combined_ClinicianFeedback_2019-06-14_Post_01Aug2019_final.pdf 10167BrigatinibNSCLC_Combined_PtGrp_COIs_Post_01Aug2019_final_Redacted.pdf 10167BrigatinibNSCLC_Combined_Clinician_COIs_01Aug2019_final_Redacted.pdf	Aug 19, 2019	Reimbursement Review		Complete	PC0167-000
Keytruda for Melanoma Adjuvant Treatment – Details	pcodr_provfund-10168-PembrolizumabKeytruda_MAT.pdf 10168PembrolizumabMAT_FnRec_31 July 2019__Post_01Aug2019_final.pdf 10168PembrolizumabMAT_fnEGR_NOREDACT-ABBREV_Post_01Aug2019_final.pdf 10168PembrolizumabMAT_fnCGR_REDACT_Post_01Aug2019_final.pdf 10168PembrolizumabMAT_inRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf 10168PembolizumabMAT_PAGFeedbackSummary_FINAL_Post_01Aug2019_final.pdf 10168PembrolizumabMAT_SubmitterFeedback_2019-06-12_Post_01Aug2019_final.pdf 10168PembrolizumabMAT_ClinicianFeedback_CCO_2019-06-14_Post_01Aug2019_final.pdf 10168PembrolizumabMAT_Combined_Patient_COIs_Post_01Aug2019_final_Redacted.pdf 10168PembrolizumabMAT_Combined_Clinician_COIs_Post_01Aug2019_final.pdf	Aug 19, 2019	Reimbursement Review		Complete	PC0168-000
Axicabtagene Ciloleucel for Adults With Relapsed or Refractory Large B-cell Lymphoma		Aug 15, 2019	Health Technology Review	Optimal Use	Completed	CT0002-000
vilazodone		Aug 15, 2019	Reimbursement Review		Not filed	NS0006-000
ibrutinib		Aug 15, 2019	Reimbursement Review		Not filed	NS0009-000
eltrombopag		Aug 15, 2019	Reimbursement Review		Not filed	NS0007-000
tezacaftor/ivacaftor		Aug 15, 2019	Reimbursement Review		Not filed	NS0008-000
Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Recommendations		Aug 15, 2019	Health Technology Review		Completed	CT0002-000
Lenvima for Hepatocellular Carcinoma – Details	pcodr-profund-10175-LenvatinibLenvima_HCC.pdf 10175LenvatinibHCC_fnRec_2019-07-23_ApprovedByChair_Post_24Jul2019_final.pdf 10175LenvatinibHCC_inEGR_NOREDACT-ABBREV_EarlyCon_Post_24Jul2019_final.pdf 10175LenvatinibHCC_inCGR_NOREDACT_EarlyConv_Post_24Jul2019_final.pdf 10175LenvatinibHCC_inRec_ApprovedByChair_NOREDACT_Post_05Jul2019_final.pdf 10175LenvatinibHCC_PAGFeedbackSummary_FINAL_Post_24Jul2019_final.pdf 10175LenvatinibHCC_SubmitterFeedback_2019-07-19_Post_24Jul2019_final.pdf 10175LenvatinibHCC_Canadian Liver Foundation v2 2019-07-22_Post_24Jul2019_final.pdf 10175LenvatinibHCC_ClinicianFeedback_BCCancer_2019-07-18_Post_24Jul2019_final.pdf 10175LenvatinibHCC_CombinedPat_Post_24Jul2019_Redacted.pdf 10175LenvatinibHCC_Combined Clinician COIs_Post_24Jul2019_final.pdf	Aug 13, 2019	Reimbursement Review		Complete	PC0175-000
RFA: Bosulif for Chronic Myeloid Leukemia – Details	pcodr-profund-rfa-0002-bosutinib.pdf RFA0002BosutinibCML_FnRec_2019-07-31_Post_01Aug2019_final.pdf RFA0002BosutinibCML_RFA-ClinicalReport_Post_01Aug2019_final.pdf RFA0002BosutinibCML_RFA_Post_01Aug2019_final.pdf RFA0002BosutinibCML_PatientInput_CML_2019-04-24_Post_01Aug2019_final.pdf	Aug 2, 2019	Reimbursement Review		Complete	PA0002-000
Buprenorphine-Naloxone Tablet Versus Methadone for the Treatment of Patients with Opioid Use Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1150 Suboxone vs.pdf	Jul 31, 2019	Health Technology Review	Summary with Critical Appraisal	Completed	RC1150-000
CADTH Pharmaceutical Reviews Update — Issue 9		Jul 31, 2019	Reimbursement Review	Pharmaceutical Review Update
Ninlaro for Multiple Myeloma (2nd-beyond) – Details	pcodr-provfund-10164-ixazomib-ninlaro_mm2nd-beyond.pdf 10164IxazomibMM_fnRec_2019-07-05_ChairApproved_Post_05Jul2019_final.pdf 10164IxazomibMM_fnEGR_NOREDACT-ABBREV_Post_05Jul2019_final.pdf 10164IxazomibMM_fnCGR_REDACT_Post_05Jul2019_final.pdf 10164IxazomibMM_inRec_2019-05-03_Approved_Post_03May2019_final.pdf 10164IxazomibMM_PAGFeedbackSummary_FINAL_Post_5Jul2019_final.pdf 10164IxazomibMM_SubmitterFeedback_2019-05-17_Post_05Jul2019_final.pdf 10164IxazomibMM_PatientFeedback_MC_2019-05-15_Post_05Jul2019_final.pdf 10164IxazomibMM_ClinicianFeedback_CCO_2019-05-16_Post_05Jul2019_final.pdf 10164IxazomibMM_Patient_COI_MC_2018-12-13_Post_05Jul2019_final_Redacted.pdf 10164IxazomibMM_Combined COIs_Post_05Jul2019_final Redacted.pdf	Jul 22, 2019	Reimbursement Review		Complete	PC0164-000
Abemaciclib for advanced or metastatic Breast Cancer – Details	pcodr-provfund-10161-AbemaciclibVerzenio_ABC.pdf 10161AbemaciclibMBC_fnRec_ApprovedbyChair_v01_2019-07-04_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_fnEGR_NOREDACT-ABBREV_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_fnCGR_NOREDACT_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_inRec_ApprovedbyChair_v01_Post_03May2019_final.pdf 10161AbemaciclibMBC_PAGFeedbackSummary_FINAL_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_SubmitterFeedback_2019-05-17_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_Combined PatientFeedback_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_ClinicianFeedback_CCO_2019-05-16_Post_05Jul2019_final.pdf 10161AbemaciclibMBC_Combined Patient COIs_ Post_05Jul2019_final.pdf 10161AbemaciclibMBC_Combined COIs_Post_05Jul2019_final.pdf	Jul 22, 2019	Reimbursement Review		Complete	PC0161-000
buprenorphine	SR0579 Sublocade - CDEC Final Recommendation June 21, 2019_for posting.pdf sr0579-sublocade-clinical-review-report.pdf sr0579-sublocade-pharmacoeconomic-review-report.pdf	Jul 16, 2019	Reimbursement Review		Complete	SR0579-000
Revlimid (in combo) bortezomib + dexamethasone for newly diagnosed Multiple Myeloma – Details	pcodr-provfund-10141-LenalidomideRevlimid_MM.pdf 10141LenalidomideBorDexMM_fnRec_2019-06-19_ApprovedbyChair_EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_fnEGR_NOREDACT-ABBREV_EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_fnCGR_REDACT_EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_inRec_approvedbyChair_NOREDACT_Post_31May2019_final.pdf 10141LenalidomideBorDexMM_PAGFeedbackSummary_FINAL__EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_SubmitterFeedback_2019-06-14_EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_ClinicianFeedback_CCO_2019-06-14__EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_PatientCOI_MC_2019-01-11_EC-Post_19Jun2019_final.pdf 10141LenalidomideBorDexMM_Clinician_Combined_COIs_Post_19Jun2019_final_Redacted.pdf	Jul 5, 2019	Reimbursement Review		Complete	PC0141-000
cysteamine	SR0595 Cystadrops - CDEC Final Recommendation June 20, 2019_for posting.pdf sr0595-cystadrops-clinical-review-report.pdf sr0595-cystadrops-pharmacoeconomic-review-report.pdf	Jul 3, 2019	Reimbursement Review		Complete	SR0595-000
cerliponase alfa	SR0574 Brineura - Final CDEC Recommendation May 27, 2019_for posting.pdf sr0574-brineura-clinical-review-report.pdf sr0574-brineura-pharmacoeconomic-review-report.pdf sr0574-brineura-patient-input.pdf	Jun 28, 2019	Reimbursement Review		Complete	SR0574-000
halobetasol propionate and tazarotene		Jun 19, 2019	Reimbursement Review		Withdrawn	SR0600-000
efinaconazole	SR0577 Jublia - CDEC Final Recommendation May 27, 2019_for posting.pdf sr0577-jublia-clinical-review-report.pdf sr0577-jublia-pharmacoeconomic-review-report.pdf sr0577-jublia_patient-input.pdf	Jun 18, 2019	Reimbursement Review		Complete	SR0577-000
Vizimpro for Non-Small Cell Lung Cancer – Details	pcodr-provfund-10129-dacomitinib-vizimpro.pdf 10129DacomitinibNSCLC_FnRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf 10129DacomitinibNSCLC_fnEGR_NOREDACT-ABBREV_Post_31May2019_final.pdf 10129DacomitinibNSCLC_fnCGR_NOREDACT_Post_31May2019_final.pdf 10129DacomitinibNSCLC_InRec_POST04Apr2019_NOREDACT_final.pdf 10129DacomitinibNSCLC_PAGFeedbackSummary_FINAL_Post_31May2019_final.pdf 10129DacomitinibNSCLC_SubmitterFeedback_2019-04-18_Post_31May2019_final.pdf 10129DacomitinibNSCLC_ClinicianFeedback_CCO_2019-04-18_Post_31May2019_final.pdf 10129DacomitinibNSCLC_Patient_Combined_COIs_ForPosting_31May2019_final.pdf 10129DacomitinibNSCLC_Clinician_Combined_COIs_Post_31May2019_final.pdf	Jun 17, 2019	Reimbursement Review		Complete	PC0129-000
Keytruda for Non-Squamous NSCLC – Details	pcodr-provfund-10153-pembrolizumab-keytruda-non-squamous_nsclc.pdf 10153PembroNSQ-NSCLC_FnRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf 10153PembroNSQ-NSCLC_fnEGR_NOREDACT-ABBREV_Post_31May2019_final.pdf 10153PembroNSQ-NSCLC_fnCGR_REDACT_Post_31May2019_final.pdf 10153PembroNSQ-NSCLC_InRec_POST04Apr2019_NOREDACT_corrected.pdf 10153PembroNSQ-NSCLC_PAGFeedbackSummary_FINAL_Post_31May2019_final.pdf 10153PembroNSQ-NSCLC_SubmitterFeedback_2019-04-18_Post_31May2019_final.pdf 10153PembroNSQ-NSCLC_ClinicianFeedback_CCO_2019-04-18_Post_31May2019_final.pdf 10153PembroNSQ-NSCLC_Patient_Combined COIs_ForPosting_31May2019.pdf 10153PembroNSQ-NSCLC_Clinician_Combined COIs_Post_31May2019_final.pdf	Jun 17, 2019	Reimbursement Review		Complete	PC0153-000